Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Kineret anakinra Still's disease Withdrawn
TBC Darunavir / cobicistat HIV infection Withdrawn
Picato Ingenol mebutate Actinic keratosis Complete
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn
Fampyra Fampridine Multiple sclerosis, improve walking disability Withdrawn
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn
Hemangiol Propranolol Infantile hemangioma Withdrawn
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia Withdrawn